Business

AI-generated text

Isomorphic Labs raises $5 billion to advance AI-designed drugs

Isomorphic Labs has raised $5 billion in a Series C round as it prepares to move its drug candidates into clinical trials.

Isomorphic Labs raises $5 billion to advance AI-designed drugs

Isomorphic Labs has raised $5 billion in a Series C funding round as it prepares to take its drug candidates into clinical trials. The AI drug-discovery company was spun out of Google’s DeepMind in 2021.

The round was co-led by Greenoaks and Sequoia Capital, with participation from new investor Andreessen Horowitz and others. All of the company’s existing backers also invested, including Alphabet’s venture divisions GV and Capital G, as well as Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund.

From the lab to clinical trials

Isomorphic Labs is building a drug-design engine that uses a range of AI simulation models covering different areas of chemistry to help design medicines. Its work builds on DeepMind’s AlphaFold, a model that predicts the structure of proteins. The company said its program had produced positive preclinical results in oncology and immunology.

The company has also struck agreements with major pharmaceutical firms, including Eli Lilly, Novartis and Johnson & Johnson. It plans to use the new funding to further develop its drug-design engine and expand into more types of medicine. The Series C follows a $2.1 billion Series B round in May.

Leadership change and valuation

This is Isomorphic Labs’ first fundraising round since its founder and CEO, Demis Hassabis, stepped down as head of DeepMind to focus on drug discovery and became its chairman. Hassabis and John Jumper, then a director at DeepMind, received the Nobel Prize in chemistry for their work on AlphaFold. The system can predict the three-dimensional structure of proteins from their genetic sequence.

Isomorphic Labs did not disclose its valuation in the new round. Bloomberg reported earlier in the month that the lab was seeking funding at a $50 billion valuation.